On Demand Pharmaceuticals Announces Preferred Supplier Relationship with Azzur Group

Published on : Published by : BioBuzz Media

On Demand Pharmaceuticals Announces Preferred Supplier Relationship with Azzur Group
NEWS PROVIDED BY
On Demand Pharmaceuticals
Jun 01, 2022, 12:00 ET
SHARE THIS ARTICLE
Building Off Success of Commissioned cGMP Facility
ROCKVILLE, Md., June 1, 2022 /PRNewswire/ — On Demand Pharmaceuticals, Inc. (ODP), an innovative technology company transforming the way medicines are made, announced today that it has signed a Preferred Supplier agreement with Azzur Group through 2024. The transformation of ODP’s Rockville Headquarters into a State-of-the-Art cGMP Medicine Manufacturing facility began with Azzur in the fall of 2020.
Azzur collaborated in designing ODP’s GMP Roadmap and helped develop the strategy and execution plan for ushering in this latest addition to Maryland’s Biotech Hub. Building on the strategy, Azzur worked alongside ODP to initiate a Managed Services approach to execution, providing a single source for Commissioning services, Equipment rentals, Technology subscriptions, and a series of outsourced packages covering Environmental Monitoring, Training, and Documentation.
Dr. John Lewin, ODP’s Chief Medical Officer, said “The flexibility Azzur demonstrated to accommodate the fluid nature of a startup and the challenges we all faced during the COVID-19 pandemic was remarkable. Having the ability to pull on a variety of resources and expertise, when we needed…

Partnering Webinar: Detection of SARS-CoV-2 and other RNA Viruses Using a Novel Improved RT-qPCR Method that Increases Detection Sensitivity and Improves Safety

Published on : Published by : Chris Frew

NIH researchers will highlight a novel Covid-19 diagnostic technology from the National Eye Institute (NEI). NEI is seeking partners for collaboration and licensing to accelerate technology development and clinical benefit. [….]

2021 Technology Showcase

Published on : Published by : Chris Frew

Hear from inventors from the National Cancer Institute and the Frederick National Laboratory about technologies primed for commercialization and/or collaboration; great opportunity for biotech stakeholders and companies of all sizes, [….]

NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

Published on : Published by : Chris Frew

TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST. Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV [….]

NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound”

Published on : Published by : BioBuzz Media

The National Cancer Institute (NCI), Technology Transfer Center (TTC) will host a webinar to highlight a cancer therapeutic technology for collaborative development and/or licensing. The webinar presented by the technology inventor, Dr. Joel Morris, will highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight. Registration is free.

5 Questions with Amy Adams, Executive Director of the Institute for Biohealth Innovation at George Mason University

Published on : Published by : Andy Eckert

As Executive Director of the Institute for Biohealth Innovation at George Mason University, Amy Adams is responsible for nurturing and advancing biohealth research and innovation interests of more than 250 faculty and thousands of students who represent a broad range of academic disciplines. Her role includes fostering partnerships with industry, healthcare, government, and academic partners.